Short-term effect of zidovudine on plasma and genital human immunodeficiency virus type 1 and viral turnover in these compartments
Date
2003-07Author
Mbori-Ngacha, DA
Richardson, BA
Overbaugh, J
Panteleeff, DD
Nduati, RW
Steele, M
John-Stewart, G
Type
ArticleLanguage
enMetadata
Show full item recordAbstract
The effect of zidovudine on plasma and genital human immunodeficiency virus type 1 (HIV-1) was determined in 42 antiretroviral-naive HIV-1-seropositive women in Nairobi. After 7 days of zidovudine treatment, HIV-1 RNA levels decreased by 0.5 to 1.1 log(10) in plasma and genital secretions. HIV-1 RNA half-life following zidovudine treatment was 4.7, 1.3, and 0.9 days in plasma, cervix, and vagina, respectively, and significantly shorter in genital secretions than in plasma (P < 0.001). Defining the short-term effect of zidovudine on plasma and genital HIV-1 is important for improving perinatal HIV-1 interventions
URI
http://www.ncbi.nlm.nih.gov/pubmed/12805473http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/30446
Citation
J Virol. 2003 Jul;77(13):7702-5.Publisher
University of Nairobi. Department of Pediatrics, University of Nairobi, Nairobi, Kenya
Collections
- Faculty of Health Sciences (FHS) [10377]